As secondary plant metabolites, polyphenols are abundant in fruits and vegetables. They are in high demand because of their many health benefits. However, their low bioavailability makes them complex compounds to use for therapeutic purposes. Due to the limited solubility of phytocompounds, dietary supplements made from them may only be partially effective. Such molecules include fisetin, found in strawberries, and have shown great promise in treating Alzheimer’s disease and cancer. Unfortunately, because of their limited water solubility, low absorption, and poor bioavailability, the assistance of nanotechnology is required to allow them to fulfil their potential fully. Here, we provide evidence that nanodelivery methods and structure modifications can improve fisetin bioavailability, which is linked to improvements in therapeutic efficacy. An open question remains as to which nanocarrier should be chosen to meet the abovementioned requirements and be able to enhance fisetin’s therapeutic potential to treat a particular disease.

The review presents recent examples of heterogenic catalysts based on porphyrins and phthalocyanines loaded on mesoporous materials, such as MCM-41, SBA-15, MCM-48, SBA-16 or Al-MCM-41. Heterogenic approach to catalysis eases recovery, reuse and prevent macrocycle aggregation. In this application, mesoporous silica is a promising candidate for anchoring macrocycle and obtaining a new catalyst. Introduction of porphyrin or phthalocyanine into the mesoporous material may be performed through adsorption of the macrocycle, or by its in situ formation—by reaction of substrates introduced to the pores of the catalytic material. Catalytic reactions studied are oxidation processes, focused on alkane, alkene or arene as substrates. The products obtained are usually epoxides, alcohols, ketones, aldehydes or acids. The greatest interest lies in oxidation of cyclohexane and cyclohexene, as a source of adypic acid and derivatives. Some of the reactions may be viewed as biomimetic processes, resembling processes that occur in vivo and are catalyzed by cytochrome P450 enzyme family.

The health benefits of ginger rhizomes (Zingiber officinale Roscoe) have been known for centuries. Recently, ginger root has gained more attention due to its anti-inflammatory and analgesic activities. Many of the bioactive components of ginger may have therapeutic benefits in treating inflammatory arthritis. Their properties seem especially helpful in treating diseases linked to persistent inflammation and pain, symptoms present in the course of the most prevalent rheumatic diseases, such as osteoarthritis (OA) and rheumatoid arthritis (RA). This review analyzes the current knowledge regarding ginger’s beneficial anti-inflammatory effect in both in vitro and in vivo studies as well as clinical trials. The drug delivery systems to improve ginger’s bioavailability and medicinal properties are discussed. Understanding ginger’s beneficial aspects may initiate further studies on improving its bioavailability and therapeutic efficacy and achieving more a comprehensive application in medicine.